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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a lethal X-linked
neuromuscular disease that affects 1 in 3500 boys. Clinical symptoms
are first detected at 2-5 years of age and individuals with DMD often
die from cardiac or respiratory failure by the second or third decade
of life. DMD is caused by mutations in the dystrophin gene that lead
to loss of the dystrophin protein (Monaco et al., 1986; Hoffman et
al., 1987). Dystrophin and the associated protein complex link
laminin in the extracellular matrix to the cell cytoskeleton and serves
as a structural and signaling platform in muscle. Loss of dystrophin
in the mdx mouse, golden retriever muscular dystrophy (GRMD)
dog and DMD patients results in a fragile sarcolemma prone to
contraction-induced muscle injury. Damaged muscle activates
satellite cells to repair muscle damage, and rounds of muscle
degeneration followed by regeneration occurs. Regeneration
eventually fails and muscle is replaced with fibrotic and fatty tissue
(Pichavant et al., 2011). There is currently no cure for DMD: however,
improved medical care and treatment with corticosteroids,
prednisone or deflazacort have improved muscle strength and
longevity of patients (Fenichel et al., 1991; Angelini et al., 1994; Reitter,
1995; Merlini et al., 2003; Beenakker et al., 2005).
The mdx mouse model has provided valuable insights into the
functional role of dystrophin in muscle. Although these mice exhibit
muscle damage at the cellular level, outwardly they show little sign
of muscle pathology (Bulfield et al., 1984). Short-term prednisone
therapy in the mdx mouse has been shown to improve muscle
strength (Sali et al., 2012). The GRMD dog model develops
progressive and fatal muscle disease and exhibits pathophysiological
disease features similar to DMD, including progressive loss of
muscle function, muscle membrane fragility, cardiomyopathy and
premature death (Cooper et al., 1988; Kornegay et al., 1988;
Kornegay et al., 2012). Studies indicate that short-term treatment
with prednisone has functional benefits in the GRMD model (Liu
et al., 2004). Although corticosteroids are the current front line
treatment for DMD and show short-term benefits in animal models
of this disease, the mechanism(s) by which this drug improves
clinical outcomes remains unknown.
α7β1 integrin is the predominant laminin-binding integrin in
cardiac and skeletal muscle (Burkin and Kaufman, 1999). The α7β1
integrin protein is localized at neuromuscular and myotendinous
junctions and extrajunctional sites in skeletal muscle (Martin et al.,
1996; Burkin and Kaufman, 1999). In skeletal muscle, six isoforms
of the α7 integrin chain are produced by developmentally regulated
RNA splicing (Song et al., 1993). Mutations in the α7 integrin gene
cause congenital myopathy in both humans and mice (Mayer et al.,
1997; Hayashi et al., 1998; Flintoff-Dye et al., 2005). Enhanced
transgenic expression of α7 integrin in the skeletal muscle of severely
dystrophic mice improves muscle pathology and increases lifespan
(Burkin et al., 2001; Burkin et al., 2005). Conversely, loss of α7 integrin
in dystrophin-deficient mdxmice results in a more severe dystrophic
phenotype and reduced viability, with mice dying prematurely by 4
weeks of age (Guo et al., 2006; Rooney et al., 2006). Together, these
results support the idea that α7β1 integrin is a modifier of muscle
disease progression in DMD and a target for drug-based therapies.
To investigate whether glucocorticoids act to increase α7β1
integrin in muscle, we examined levels of α7 integrin in myogenic
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SUMMARY
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease for which there is no cure and limited treatment options. Prednisone is currently
the first line treatment option for DMD and studies have demonstrated that it improves muscle strength. Although prednisone has been used for
the treatment of DMD for decades, the mechanism of action of this drug remains unclear. Recent studies have shown that the α7β1 integrin is a
major modifier of disease progression in mouse models of DMD and is therefore a target for drug-based therapies. In this study we examined
whether prednisone increased α7β1 integrin levels in mdx mouse and GRMD dog models and myogenic cells from humans with DMD. Our results
show that prednisone promotes an increase in α7 integrin protein in cultured myogenic cells and in the muscle of mdx and GRMD animal models
of DMD. The prednisone-mediated increase in α7 integrin was associated with increased laminin-α2 in prednisone-treated dystrophin-deficient
muscle. Together, our results suggest that prednisone acts in part through increased merosin in the muscle basal lamina and through sarcolemmal
stabilization of α7β1 integrin in dystrophin-deficient muscle. These results indicate that therapies that target an increase in muscle α7β1 integrin,
its signaling pathways and/or laminin could be therapeutic in DMD.
Levels of α7 integrin and laminin-α2 are increased
following prednisone treatment in the mdx mouse and
GRMD dog models of Duchenne muscular dystrophy
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cells from individuals with DMD as well as in the mdx mouse and
GRMD dog animal models of DMD treated with prednisone. Our
results show that treatment with prednisone promotes a dose-
dependent increase in α7 integrin in mouse and DMD myogenic
cells. In addition, we show the skeletal muscle of mdx mice and
GRMD dogs treated with prednisone exhibit elevated levels of
laminin-α2 and α7 integrin. Our results show for the first time that
prednisone promotes an increase in the α7β1 integrin in muscle,
which might contribute to the mechanism of action of this
important therapeutic agent for DMD.
RESULTS
Prednisone increases α7 integrin levels in a mouse model and in
DMD myogenic cells
Corticosteroids are used to treat many chronic diseases, including
DMD. In many cases, the benefits of prednisone treatment are
known to occur through anti-inflammatory effects. However,
inflammatory suppression does not explain the short-term benefits
to muscle strength in DMD patients and the overall delay of muscle
degenerative symptoms. Previous studies have shown reduced
muscle pathology and improved strength in transgenic mdx/utr−/−
mice (lacking both dystrophin and utrophin) that overexpress α7B
integrin (Burkin et al., 2001). We hypothesized that increased α7
integrin might be one of the mechanisms by which prednisone
functions to improve muscle strength in DMD. In order to test this
hypothesis, C2C12 mouse myoblasts and myotubes were treated
with increasing concentrations of prednisone for 48  hours, and
levels of α7B integrin protein were analyzed by western analysis
and normalized to levels of α-tubulin (Fig. 1A,B). In C2C12
myoblasts, treatment with prednisone had no significant effect on
α7B integrin levels compared with DMSO-treated control cells
(Fig. 1A, quantified in 1C). In contrast, C2C12 myotubes showed
a dose-dependent increase in α7B integrin compared with DMSO-
treated control cells (Fig.  1B, quantified in 1D). Prednisone
treatments of 112 μM and 176 μM resulted in a 1.6- and 1.8-fold
increase in α7B integrin protein in myotubes, respectively,
compared with DMSO alone. The highest dose of prednisone the
cells were exposed to was 176 μM, which also gave the largest α7
integrin increase (Fig. 1D). This maximum dose was limited by both
the solubility of prednisone in DMSO and cell toxicity, which was
shown at >1% DMSO. These data indicate that prednisone
promotes an increase in α7B integrin protein in a dose-dependent
manner in cultured mouse myotubes.
Next, we examined whether prednisone treatment increased α7
integrin in human DMD myotubes. Western analysis showed that
DMD myotubes treated with 112 μM prednisone had a 1.8-fold
increase in α7B integrin protein compared with those treated with
DMSO (Fig.  1E, quantified in 1F). These results confirm that
prednisone acts to increase α7 integrin in a conserved pathway in
both mouse and human myotubes.
Prednisone increases α7 integrin in mdx mouse muscle
The mdx mouse model for DMD was used to examine the effect
of prednisone treatment on α7 integrin levels in the muscle of mice.
PBS (n=9) or 1 mg/kg prednisone in PBS (n=7) was given daily by
oral gavage to 3-week-old mdx mice. Treatment was performed
for 2 weeks, at which time the mice were sacrificed and tissues
harvested for analysis. We then analyzed the protein levels of α7A
integrin from both the tibialis anterior (TA) and gastrocnemius
muscles in prednisone-treated versus control mdx mice (Fig. 2A,B,
respectively). In the TA we found a non-significant trend of
elevated α7A integrin protein levels (~13% increase) by western
analysis (Fig. 2A); however, a significant increase (~30% increase)
was observed in prednisone-treated gastrocnemius muscles
compared with controls (Fig.  2B). Results were quantified and
normalized to α-tubulin (Fig. 2C,D). This differential effect is not
completely surprising because previous work has shown that the
TA muscle maintains lower levels of β1 integrin than the
gastrocnemius muscle (Masuda et al., 2009). These results indicate
that short-term treatment with prednisone increases α7A integrin
in the muscle of mdx mice. Next, we examined the distribution of
α7A integrin in the TA muscle by immunofluorescence (IF; Fig. 2E).
Compared with PBS-treated mice, prednisone-treated animals
showed an increase in α7A integrin at the sarcolemma, confirming
western studies. These results suggest that short-term prednisone
dmm.biologists.org2
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TRANSLATIONAL IMPACT
Clinical issue
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that
affects 1 in 3500 newborn boys and is caused by mutations in the gene
encoding dystrophin, a protein that supports muscle fiber strength. Loss of
dystrophin results in reduced muscle cell adhesion to laminin in the basal
lamina, which leads to progressive muscle damage. DMD is diagnosed at 3-5
years of age on the basis of failure to achieve movement-based milestones.
Individuals with DMD are often confined to a wheelchair in their teens, require
ventilator assistance to breathe and die in their second or third decade of life
as a result of cardiopulmonary failure. There is currently no cure for DMD and
treatment options are limited to glucocorticoid therapy, which has been
shown to improve clinical outcomes including increased muscle strength.
Although prednisone, a synthetic corticosteroid drug, has been used to treat
DMD for decades, the molecular mechanisms that underlie the improvement
in muscle strength are unknown.
Results
In this study the authors aimed to determine whether prednisone acts to
increase levels of 71 integrin, an adhesion molecule previously shown to
ameliorate muscle disease in mouse models of DMD. Using muscle cells
cultured from mice or DMD patients, the authors show that prednisone acts to
increase protein levels of 7 integrin in a dose-dependent manner. They also
report that prednisone treatment in the well-established mdx mouse model of
DMD and the GRMD canine model increases protein levels of 71 integrin, as
well as those of laminin-2, which makes up a component of the basement
membrane. Finally, the authors show that GRMD dogs that have not been
treated with prednisone exhibit reduced levels of laminin-2 and 7 integrin
proteins.
Implications and future directions
In this translational study the authors provide evidence that prednisone, the
current front line treatment for DMD, acts in part to increase laminin-211/221
(composed of 2, 1 and 1 chains) in the muscle basal lamina to stabilize
protein levels of 71 integrin in skeletal muscle cells. These changes would
lead to improvements in muscle fiber integrity in dystrophin-deficient muscle
to slow the disease process. The results also suggest a shared mechanism for
disease progression in GRMD dogs and humans, reinforcing the view that the
canine model provides a useful tool for studies of the human disease. Despite
the beneficial effects of prednisone, the improvement is temporary and,
furthermore, therapy is complicated by the wide range of associated negative
side effects. Future studies to identify drugs that specifically target an increase
in laminin-2 and/or 71 integrin in muscle are likely to improve clinical
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treatment within the mdx mouse model results in an increase in
the α7A integrin protein levels at the sarcolemma.
Next, we assessed whether the prednisone-induced increase in
α7A integrin protein levels in the mdx mouse was due to protein
stabilization or increased transcription of the Itga7 gene in muscle
fibers. Quantitative real-time PCR was used to examine the
transcript levels of Itga7, Lama2, Lama4, Lama5 and Utrn relative
to GapDH within the TA muscle of the PBS- and prednisone-
treated mice (Fig. 3A-E). A 30% increase in Itga7 transcript levels
was observed with prednisone treatment, but this value did not
reach significance (Fig.  3A). Similar results were obtained from
triceps muscle, where prednisone treatment led to a 40% increase
in Itga7 transcript levels, albeit insignificant (supplementary
material Fig. S1). These results indicate that the increased level of
α7 integrin that is observed in prednisone-treated mdxmuscle likely
occurs through a transcriptionally based mechanism.
To explore the mechanism by which prednisone increased α7
integrin protein levels in skeletal muscle, we examined the
transcription of laminin isoforms and utrophin in PBS- and
prednisone-treated mdx mice. Recent studies have demonstrated
that deflazacort increases laminin-α2 levels in the muscle of mdx
mice (Anderson et al., 2000). Our results show that, compared with
PBS, prednisone promoted a significant increase in Lama2
transcripts in the TA (Fig. 3B) and triceps (supplementary material
Fig. S1) muscles of mdx mice. There was no significant change in
the levels of Lama4, Lama5 or Utrn transcripts (Fig.  3C-E) in
prednisone-treated mice. Together, these results indicate that
prednisone might act to alter the laminin composition of the
myomatrix and promote an increase in laminin-211 and laminin-
221 in mdxmuscle. The presence of more laminin-211 and laminin-
221 in skeletal muscle basal lamina would promote stabilization of
the α7β1 integrin complex in skeletal muscle, thus improving the
integrity of the dystrophin-deficient sarcolemma.
Prednisone increases α7A integrin in the muscle of GRMD dogs
We next examined whether prednisone treatment increased α7
integrin levels in the GRMD canine model of DMD. We began by
examining α7A integrin protein levels in the vastus lateralis (VL)
muscle of 6-month-old wild-type, untreated GRMD dogs and
prednisone-treated GRMD dogs. Using western blotting and
quantitation techniques, we found a 1.7-fold increase in the levels
of α7A integrin protein in the prednisone-treated GRMD dogs
compared with either wild-type or untreated GRMD dogs (Fig. 4A,
quantified in 4B). Although not significantly different, the average
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Fig. 1. Effects of prednisone on α7 integrin levels in C2C12
mouse myoblasts and myotubes, and human DMD myotubes.
(A,B)Western blot analysis of α7B integrin and α-tubulin from
C2C12 myoblasts (A) or myotubes (B) treated with a DMSO control
or increasing amounts of prednisone. (C,D)Quantitation of α7B
integrin levels normalized to α-tubulin was performed and
graphed for the C2C12 myoblast (C) and myotube (D) treatments
(n=4 per treatment group, **P<0.01, ***P=0.0005). (E)Western blot
analysis of α7B integrin and GapDH from cultured human DMD
myotubes. (F)Western results were quantified and graphed for
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α7A integrin protein levels in untreated GRMD muscle were found
to be 25% lower than that of the wild-type dogs (Fig. 4A, quantified
in 4B). Furthermore, we found increased sarcolemmal-localized
α7A integrin within the VL muscle of GRMD animals by
immunofluorescence (Fig. 4C).
We next examined ITGA7 transcript levels in the VL muscle
of dogs using quantitative real-time PCR (Fig. 4D). Surprisingly,
we found that the ITGA7 transcript levels in prednisone-treated
GRMD dogs were ~twofold lower than untreated wild-type levels
(Fig.  4D). Furthermore, although not statistically significant
(P=0.08), the prednisone-treated GRMD dogs had average ITGA7
transcript levels that were threefold lower compared with the
levels in untreated GRMD dogs (Fig.  4D). Similar to previous
findings from individuals with DMD (Hodges et al., 1997), we
found a twofold increase in the average ITGA7 transcript levels
in untreated GRMD dogs compared with wild-type dogs (Fig. 4D),
although again this difference was not statistically significant
owing to the high variability of the transcript levels in the
untreated GRMD dogs. This variability was not apparent in the
ITGA7 transcript levels of prednisone-treated GRMD dogs
(Fig. 4D). Together, these results along with western data in the
dog model suggest that the improved α7 integrin protein stability
caused by prednisone treatment results in a negative feedback
loop on ITGA7 transcriptional activity.
dmm.biologists.org4
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Fig. 2. mdx mice treated with prednisone (1 mg/kg body weight/day) have
increased α7A integrin in muscle. (A,B)PBS-control (n=9) or 1 mg/kg/day
prednisone (n=7)-treated mdx mouse TA (A) or gastrocnemius (B) muscle
extracts analyzed for α7A integrin and α-tubulin protein levels using standard
western blotting procedures. (C,D)Western blots were quantitated and
graphed for α7A integrin normalized to α-tubulin for the TA (C) or
gastrocnemius (*P=0.04) (D). (E)Immunofluorescence of α7A integrin from the
TA of PBS-treated or 1 mg/kg/day prednisone-treated mdx mice. Scale bar: 
50 μm. Fig. 3. LAMA2 transcript levels are significantly elevated in prednisone-
treated mdx mouse muscle. Quantitative real-time PCR was performed
against mdx TA cDNA from animals treated with PBS (n=9) or 1 mg
prednisone/kg body weight/day (n=7), using gene-specific primers against
mouse Itga7 (A), mouse Lama2 (*P=0.03; B), mouse Lama4 (C), mouse Lama5
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Prednisone maintains laminin-α2 protein localization and levels in
GRMD dogs
Next, we determined laminin-α2 protein levels and localization in
the VL muscle of wild-type, untreated GRMD and prednisone-
treated GRMD dogs using immunofluorescence. Laminin-α2 was
clearly present surrounding the muscle fibers in both wild-type and
prednisone-treated GRMD dogs, but was only weakly visible
around untreated GRMD dog muscle fibers (Fig. 5A). Levels were
semi-quantified by performing intensity measurements on images
from wild-type, untreated GRMD and prednisone-treated GRMD
muscle (Fig. 5A). Prednisone-treated GRMD dogs showed a 32%
increase in peak relative intensity compared with wild-type muscle
(Fig. 5A). Both peak intensities were higher and had different curve
distributions than that observed for the untreated GRMD dog
images. Untreated and prednisone-treated GRMD dogs contained
numerous intense fluorescence regions of unknown origin in the
muscle interstitial space that are likely to have affected
measurements, especially in untreated GRMD dogs (Fig. 5A and
supplementary material Fig. S2). Together, these results support
that prednisone acts to increase laminin-α2 and α7 integrin protein
levels in GRMD dogs.
Next, we determined whether the canine model showed
differences in the transcript levels of LAMA2, LAMA4, LAMA5
and UTRN (Fig. 5B-E). Like the ITGA7 transcript levels, untreated
GRMD dogs showed a large amount of individual variability in
relative levels of LAMA2, LAMA4, LAMA5 and UTRN transcripts,
which was not observed in prednisone-treated GRMD dogs
(Fig. 5B-E). LAMA2 transcript levels were significantly increased
in the VL muscle in prednisone-treated (twofold) and untreated
(sixfold) GRMD dogs compared with untreated wild-type dog
(Fig.  5B). The LAMA4 (P=0.6), LAMA5 (P=0.08) and UTRN
(P=0.4) transcript levels in the prednisone-treated GRMD dogs
were not significantly different compared with untreated wild-type
dogs, but the LAMA5 average was around twofold lower (Fig. 5C-
E). LAMA4 (P=0.051), LAMA5 (P=0.03) and UTRN (P=0.13)
transcript levels were around threefold lower in prednisone-treated
GRMD dogs relative to the untreated GRMD dogs (Fig.  5C-E).
Together, this data suggests that prednisone treatment of GRMD
Disease Models & Mechanisms 5
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Fig. 4. Prednisone treatment leads to elevated α7A
integrin protein and reduced ITGA7 transcript levels
in GRMD dog muscle. (A)Representative western blot
of α7A integrin and α-tubulin protein levels from the VL
of control (n=5), untreated GRMD (n=6) and
prednisone-treated GRMD (n=4) dogs. (B)Western
results for α7A integrin normalized to α-tubulin were
quantified and graphed (*P=0.019, **P=0.0023).
(C)Immunofluorescence of α7A integrin in the VL of the
three dog groups. (D)Quantitative real-time PCR of VL
cDNA from wild-type (n=5), untreated GRMD (n=6) and
prednisone-treated GRMD (n=4) dogs using primers
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dogs stabilizes the transcriptional levels of all genes that we
examined.
We were curious as to whether lesion severity would also vary
between untreated and prednisone-treated GRMD dogs, and
examined muscle histology by hematoxylin and eosin (H&E)
staining (Fig. 5F). All GRMD dogs displayed increased myofiber
size variation, fibrosis and inflammation compared with wild-type
dogs. Changes in untreated GRMD dogs were more pronounced
dmm.biologists.org6
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Fig. 5. Prednisone restores laminin-α2 protein, stabilizes transcript levels and improves muscle pathology in the GRMD dog. (A)Immunofluorescence of
laminin-α2 protein in wild-type, untreated GRMD and prednisone-treated GRMD dog VL muscle. The intensity values for two images per dog were counted,
averaged by groups and plotted (see supplementary material Fig. S2). Quantitative real-time PCR of VL cDNA from wild-type control (n=5), untreated GRMD
(n=6) and prednisone-treated GRMD (n=4) dogs using primers against canine LAMA2 (*P<0.035) (B), canine LAMA4 (*P=0.047) (C), canine LAMA5 (*P=0.035) (D)
and canine UTRN (E). (F)H&E of the VL from control, untreated GRMD and prednisone-treated GRMD dogs. The VL sections were examined and graded (Table 1)
for fibrosis, inflammation and muscle fiber hypotrophy. Prednisone-treated GRMD dog tissue had less fibrosis, inflammation and fiber size disparity than the
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than in those treated with prednisone (Fig. 5F). Based on the overall
histology, including fiber size, fibrosis and inflammation, we scored
the VL sections between 1+ and 5+, with lower values suggesting
greater lesion severity. These values were then summarized along
with α7A integrin protein levels, laminin-α2 immunofluorescence
peak intensity, and individual real-time fold-changes for ITGA7,
LAMA2, LAMA4, LAMA5 and UTRN transcripts for all dogs used
in this study (Table 1). The prednisone-treated GRMD dogs had
higher (more normal) lesion scores. Individual profiles from some
dogs showed higher α7A integrin protein levels while exhibiting
lower levels of ITGA7 transcript and vice versa in both prednisone-
treated and untreated GRMD dogs (Table  1). A similar inverse
pattern was seen for the laminin-α2 protein:transcript ratio. Overall,
the prednisone dose did not seem to affect protein or transcript
levels in the GRMD dogs. Taken together, our data strongly suggest
that a negative feedback loop exists between α7 integrin protein
and ITGA7 transcript levels in the GRMD dog model (Fig. 6).
Furthermore, elevated levels of ITGA7 and/or LAMA2 transcripts
might be indicators of a more severe muscle disease phenotype in
DMD.
DISCUSSION
DMD is a devastating and fatal genetic disease for which there is no
cure and limited treatment options. Although corticosteroids have
been used for the treatment of DMD for over 20 years, our
understanding of the mechanism of action of these drugs remains
unclear. The therapeutic benefits of prednisone might involve a
complex combination of immune modulation and strength
enhancement in muscle. In this study we identified that prednisone
treatment promotes an increase in the α7β1 integrin protein, a known
disease modifier, in dystrophin-deficient muscle. We show that this
benefit occurs in tandem with increased laminin-211/221 in the basal
lamina of prednisone-treated muscle, suggesting that laminin might
act to stabilize α7β1 integrin at the sarcolemma (Fig. 6). Finally, we
have shown for the first time an inverse correlation between α7
integrin transcript and protein levels in the GRMD dog model for
DMD. These results could profoundly alter the way we view ITGA7
and LAMA2 transcriptionally based data in the future.
An interesting aspect of this study was the comparison of α7
integrin levels between the mdx mouse and the GRMD dog.
Disease Models & Mechanisms 7
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Table 1. Analysis of VL muscles  














grade Itga7 Lama2 Lama4 Lama5 Utrn 
Untreated wild type 
Kip M N n/a n/a 0.85 771 3.14 2.45 3.41 4.43 1.49 +++++ 
Oregano M N n/a n/a 1.02 1179 3.12 4.06 4.56 5.87 1.89 +++++ 
Parsley M N n/a n/a 0.71 529 3.76 1.88 2.31 3.58 1.33 +++++ 
Pinkman M N n/a n/a 0.89 689 1.57 1.00 1.20 1.92 1.00 +++++ 
Tuco M N n/a n/a 0.87 524 1.94 1.18 1.35 1.52 1.11 +++++ 
Untreated GRMD (affected) 
Cosmo M N n/a n/a 0.76 649 4.74 12.16 5.56 5.72 5.25 ++ 
Napoleon M N n/a n/a 0.81 476 4.21 14.39 7.32 6.22 3.30 ++  
Summer F N n/a n/a 0.23 631 4.15 16.67 6.67 6.93 2.39 +  
Dorothy F N n/a n/a 0.21 551 9.21 28.31 14.84 10.15 9.82 + 
Gaea F N n/a n/a 1.03 626 1.93 4.86 4.40 2.40 2.59 +++  
Athena F N n/a n/a 1.11 726 1.45 5.18 3.29 1.97 1.97 +++  
Prednisone-treated GRMD (affected) 
Elf F Y 1 2-6 months 1.49 1216 1.03 2.75 1.46 1.23 1.19 ++++ 
Bam Bam M Y 1 2-6 months 1.49 1064 1.66 5.44 2.57 1.73 1.82 ++++ 
Copper M Y 2 1 week to  
6 months 
1.54 611 1.00 3.91 1.00 1.00 1.07 ++++ 
Romano M Y 2 2-6 months 1.15 839 1.91 6.98 3.48 2.39 2.57 ++++ 
All dogs were aged 6 months. M, male; F, female; N, no treatment; Y, prednisone treated. 
Fig. 6. Model depicting the action of prednisone on laminin-α2 and α7
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Previous work established that α7 integrin transcript levels are
elevated in the muscle of mdx mice and in individuals with DMD
(Hodges et al., 1997). The twofold increase in the mdx mouse α7
integrin protein levels are well defined (Hodges et al., 1997);
however, the only evidence of the increase in α7 integrin protein
levels from individuals with DMD is from non-quantitative
immunofluorescence studies and α7 integrin transcript analysis
(Hodges et al., 1997). Here we examined α7 integrin protein and
transcript levels in the GRMD dog, which phenotypically resembles
DMD disease progression. As with previous work from DMD
patient tissue (Hodges et al., 1997), we found elevated α7 integrin
gene transcripts in the untreated GRMD dog muscle compared with
wild-type dogs. However, we also show that this does not correlate
with an increase in α7 integrin protein. In fact, we found that an
inverse correlation between the transcript and protein levels exists
in the untreated GRMD dystrophic tissues. This raises the question
of why this phenomenon is not present in the mdx mouse model,
where we found a direct correlation between transcript and protein
levels. GRMD dogs seem to have a negative feedback loop by which
elevated α7 integrin protein levels leads to ITGA7 transcriptional
suppression. The lack of negative feedback suppression of Itga7
transcription in the mdx mouse might allow for greater average α7
integrin protein levels at the sarcolemma than in other models. The
mouse α7 integrin protein is more stable, lacking a secondary
extracellular protease cleavage site that is conserved in rats, dogs
and humans (Liu et al., 2008b). This non-cleavable mouse α7
integrin could enable the mdx mouse to stabilize their sarcolemma
by reducing α7 integrin protein turnover, thus preventing the
dystrophic progression. The severe pathology of the mdx/α7−/−
double-knockout mouse compared with the mild dystrophy in the
mdx or α7−/− knockout mouse lines is evidence that dystrophin
and α7 integrin have overlapping roles in maintaining sarcolemmal
stability in mice (Rooney et al., 2006). The severe decrease in α7
integrin protein in several GRMD dogs suggests that, in dystrophin-
deficient dogs and probably humans, the α7 integrin protein is less
stable than in mdx mice. Furthermore, the histological appearance
of dystrophin-deficient dog muscle correlated with the levels of α7A
integrin, suggesting that α7 integrin protein levels alone might be
a major determinant of dystrophic progression. Although functional
outcomes are improved subsequent to prednisone treatment in the
GRMD model, histopathological changes suggest that long-term
treatment could have deleterious consequences (Liu et al., 2004).
Upregulation of α7β1 integrin might act to stabilize the muscle cell
membrane, while independent side effects of prednisone cause
pathological changes.
Because the α7B integrin protein is an important signaling
molecule in muscle (Boppart et al., 2006; Liu et al., 2008a; Gurpur
et al., 2009), its loss could promote a large transcriptional change
through downstream signaling. Interestingly, untreated GRMD
muscle, which had severely reduced α7 integrin protein levels, also
showed the highest transcript levels of the genes we examined in
this study. Transcript levels were comparable between prednisone-
treated GRMD and wild-type dogs, with levels of ITGA7, LAMA4
and LAMA5 lower than in wild-type dogs, presumably due to the
negative feedback loop. Thus, signaling feedback through elevated
α7B integrin protein levels might help stabilize the transcriptional
levels in the prednisone-treated GRMD dogs and greatly reduce
variation in muscle transcript levels.
Increased laminin-α2 is probably part of the mechanism through
which prednisone stabilizes and increases the α7 integrin protein
levels at the sarcolemma. Previous data has shown that laminin-
111 protein therapy increases α7 integrin in mdxmouse and human
DMD muscle cells (Rooney et al., 2009). It is interesting that
prednisone treatment led to a lower level of all transcripts observed
relative to the wild-type dog except for LAMA2 and UTRN. The
combination of increased α7 integrin, laminin-α2 and utrophin
proteins would be optimal at stabilizing the sarcolemma in the
absence of dystrophin. Together, these results suggest that the
elevated levels of laminin-211/221 in the myomatrix of dystrophic
muscle caused by prednisone treatment might act to stabilize the
α7β1 integrin at the sarcolemma, thus improving mechanical
stability and strength to dystrophin-deficient muscle but also
leading to altered signaling and transcriptional activity.
Studies in mdxmice suggest that, although short-term treatment
with prednisone improves muscle strength, long-term treatment
could have negative consequences on cardiac function (Sali et al.,
2012). Our findings suggest that treatment with prednisone acts
in part to increase laminin-α2 and α7β1 integrin protein to enhance
the adhesion of skeletal muscle to the basal lamina and improve
clinical outcomes. Some key questions remain concerning the
action of prednisone through laminin-α2 and α7β1 integrin: (1)
Why is this action of prednisone transient in dystrophin-deficient
muscle? (2) Does long-term treatment with prednisone result in
downregulation of the α7β1 integrin receptor and/or laminin in
muscle? (3) Does prednisone have a similar mechanism of action
on laminin-α2 and α7β1 integrin in the dystrophic heart? (4) Does
prednisone activate known α7β1 integrin signaling pathways in
muscle? (5) Does prednisone increase α7β1 integrin and laminin
localization at myotendinous and neuromuscular junctions? (6)
Does prednisone’s actions on laminin-α2 and α7β1 integrin extend
to other types of muscular dystrophies, e.g. merosin deficient
congenital muscular dystrophy type 1A.
What is clear from this study is that prednisone, a drug currently
used in the treatment of DMD, acts in part through stabilization
of laminin-α2 and α7β1 integrin in muscle, and our results suggest
that molecules targeting or stabilizing these proteins are likely to
be beneficial in the treatment of DMD.
MATERIALS AND METHODS
Tissue culture
C2C12 cells used in this study were purchased from ATCC and
were grown in DMEM media (GIBCO, Grand Island, NY)
supplemented with 20% fetal bovine serum (FBS, Atlanta
Biologicals, Lawrenceville, GA), 0.5% chick-embryo extract (CEE,
Seralab, West Sussex, UK), 1% L-glutamine (GIBCO, Grand Island,
NY) and 1% penicillin/streptomycin (PS) (GIBCO, Grand Island,
NY). C2C12 myoblasts were differentiated to myotubes in DMEM
supplemented with 1% horse serum, 1% L-glutamine and 1% PS.
Human DMD myoblasts were a generous gift from Dr Kathryn
North (The Royal Children’s Hospital, Victoria, Australia) and used
under an approved IRB from the University of Nevada, Reno. DMD
myogenic cells were grown in F10 media (GIBCO, Grand Island,
NY) supplemented with 20% FBS, 1% CEE, 0.5 mM CaCl2, 1% L-
glutamine and 1% PS. Human DMD myoblasts were differentiated
to myotubes in F10 media supplemented with 1% horse serum, 1%
L-glutamine and 1% PS.
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The mdx mouse line (C57Bl10scsn-Dmdmdx) (Jackson
Laboratories, Bar Harbor, ME) was used in these studies in
accordance with an animal protocol approved by the University of
Nevada, Reno, Institutional Animal Care and Use Committee. Mice
were treated with 100 μl of PBS or 100 μl of a 200 μg/ml solution
prednisone (1 mg/kg) (Sigma, St Louis, MO) by daily oral gavage
for 2 weeks beginning at 3 weeks of age. At 5 weeks, mice were
sacrificed and muscle tissues were surgically removed and frozen
using standard procedures (Rooney et al., 2009). The TA was used
for immunofluorescence, the gastrocnemius was used for western
blotting, and the tricep muscle was used for quantitative real-time
PCR.
Dog tissue
All dogs were used and cared for according to principles outlined
in the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Archived VL muscle samples from dogs
included in a prednisone preclinical trial completed at the
University of Missouri-Columbia were used (Liu et al., 2004). The
VL muscle was surgically biopsied at 6 months of age in five
untreated wild-type dogs, six untreated GRMD dogs and four
prednisone-treated GRMD dogs (two treated with 1  mg
prednisone/kg body weight/day and two treated with 2  mg
prednisone/kg body weight/day). GRMD prednisone treatment
began at either 1 week or 2 months old and continued daily until
tissue extraction (Liu et al., 2004) (see Table 1). Dogs in the 1-week
treatment group were not included in the earlier published study
(Liu et al., 2004).
Western blotting
Protein was extracted from cell pellets or tissue powdered in liquid
nitrogen as previously described (Rooney et al., 2009). Protein
quantified using a Bradford assay and equal quantities were
separated on SDS polyacrylamide gels and α7A and α7B integrin
were detected as was previously described (Rooney et al., 2009).
Protein loading was normalized to either α-tubulin (1:1000 mouse-
monoclonal, Abcam), GapDH (1:1000, goat-polyclonal, Santa Cruz
Biotechnology, Santa Cruz, CA), or the entire lane stained with
Ponceau-S or Swift Stain (G-Biosciences, St Louis, MO).
Quantitation was performed using ImageJ software.
Immunofluorescence
10-μm sections of TA muscles from mice and VL muscles from
dog were removed using a Leica Cryostat and immunofluorescence
was performed using antibodies against α7A integrin as previously
described (Song et al., 1993) or with anti-laminin-α2 antibody
[1:100 goat-polyclonal, SC-16582 (C-20), Santa Cruz Biotechnology,
Santa Cruz, CA] followed by FITC-donkey-anti-goat (1:1000,
Jackson ImmunoResearch, Baltimore, MD) and mounted using
Vectashield containing DAPI (H-1500, Vector Laboratories, CA).
Images were taken using an Olympus Fluoview FV1000 Laser
Confocal Microscope using consistent settings for all images, and
intensity evaluation was performed using FV10-ASW3.1 software
histogram function. For wild-type, untreated GRMD and
prednisone-treated GRMD laminin-α2 IF analysis, two images were
taken per dog section. Images were taken only from interior
regions of the muscle in order to reduce any potential edge effects
and to accurately reflect the overall staining of the majority of the
muscle section. Intensity counts were averaged across all images
for each dog group and graphed using GraphPad Prism software.
Quantitative real-time PCR
Total RNA from powdered mouse triceps muscle and sectioned
canine VL was isolated using Trizol (Invitrogen, Grand Island, NY)
followed by DNase treatment (Promega, Madison, WI), and cDNA
was made with random hexamers (IDTDNA) and Superscript III
(Invitrogen, Grand Island, NY) using standard procedures.
Quantitative real-time PCR was performed using Quanta Perfecta
SYBR-Green with ROX Master Mix and was run and analyzed as
previously described (Doe et al., 2011). Mouse primers for mITGA7,
mGAPDH, mLAMA4, mLAMA5 and mUTRN were used as
previously described (Doe et al., 2011). Mouse primers for
mLAMA2 were: F- 5-CTGGGAGTCAGCAGTCAGAAGAT-3
and R- 5-CTTTATGCCACTGTCCATTGCACA-3. Primers
against canine transcripts were as follows: cITGA7 F- 5-ACTG -
TCCGAGCCAATATCACCGT-3, cITGA7 R- 5-ACCAGTAG -
TCCCGCCAGCACA-3, cGapDH F- 5-CCCCAATGTATCAG -
TTGTGGATCTGA-3, cGapDH R- 5-GGTGTCACTGTTGA -
AGTCACAGGA-3, cLAMA2 F- 5-TGGGAATCAGCAGCCA -
GAAAATG-3, cLAMA2 R- 5-GACTTTATGCCACTGTCC -
ATCACA-3, cLAMA4 F- 5-GGGGAGTACCTGAATGTTCA -
CATG-3, cLAMA4 R- 5-CTACATCCAACTGAACCACATT-
TGAATCTC-3, cLAMA5 F- 5-ATGAACTTCTCCTACTCGC -
CGCT-3, cLAMA5 R- 5-TAATAGTACCGGCGGGTGACGGT-
3, cUTRN F- 5-AGCTACTCGCTGGATCCTGACCCTG-3,
cUTRN R- 5-TGGGGCAGCAAGATGGAAATGTACT-3.
Statistical analysis
All statistical analysis was performed using GraphPad Prism 5
software. Averaged data are reported as the mean ± the standard
error of the mean (s.e.m.). Comparison for two groups was
performed using a Student’s t-test and between multiple groups
using Kruskal-Wallis one-way ANOVA on ranks for nonparametric
data. P<0.05 was considered statistically significant.
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